Keywords: insite, sell, isv-403, bausch, lomb, vision, its

InSite to sell ISV-403 to Bausch & Lomb

Article | 05 January 2004

Print This

InSite Vision is to sell its drug candidate ISV-403, indicated for thetreatment of ocular infections, to Bausch & Lomb. Under the ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in